International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Targeted Drug Delivery: Revolutionizing Treatment with Precision Medicine

Aasif Firdous[1], Neha Srivastava[2]

[1] (Author) (Undergraduate student) School of Pharmaceutical Sciences RIMT University, Mandi Gobindgarh, Punjab, India-(147301)
[2] (Assistant Professor) (Co-Author) School of Pharmaceutical Sciences RIMT University, Mandi Gobindgarh, Punjab, India-(147301)

ABSTRACT :

Targeted drug delivery is a modern approach to treating diseases that focuses on sending medication directly to the specific area in the body where it's needed—whether that's an organ, tissue, or even individual cells. By concentrating the drug at the problem site, this method helps improve how well the treatment works while also cutting down on unwanted side effects. The idea is simple but powerful: guide the drug to the right place, so less of it is needed and patients experience fewer complications. Because of its potential to make treatments safer and more effective, targeted drug delivery has become a major focus in both clinical and pharmaceutical research. A wide range of carriers can be used to make this happen, including natural and synthetic biodegradable polymers, immune cells like neutrophils and fibroblasts, artificial cells, lipoproteins, liposomes, micelles, and immune micelles. Ultimately, the goal is to deliver drugs in a way that keeps them active longer, protects them from being broken down too soon, and ensures they do their job exactly where they're needed.

Introduction

The way a drug works in the body is largely influenced by its pharmacological characteristics and its interaction with specific receptors at the site where it's meant to act. For a drug to be effective, it needs to reach this target site at the right concentration and timing, while also keeping side effects to a minimum [1]. This is the main goal of targeted drug delivery. This advanced therapeutic approach ensures that medications are transported directly to the intended tissues or cells, reducing their exposure to the rest of the body [2]. Unlike traditional delivery methods that rely on passive movement across biological membranes, targeted systems emphasize accuracy. This approach not only boosts the drug's effectiveness but also greatly lowers the chances of unwanted side effects [3].

Conventional drug delivery methods—like injections, oral pills, capsules, suspensions, and topical creams—come with their own set of challenges. For example, injectable (parenteral) routes tend to be invasive and often provide only short-term relief [4]. While oral administration is commonly used and generally convenient, it's not suitable for all drugs, particularly peptides, which may be broken down in the digestive tract or poorly absorbed [5]. Topical treatments, on the other hand, usually offer only local effects and are not effective for systemic conditions [6]. Recent advances in drug delivery technologies now offer improved control over how drugs are absorbed, distributed, and metabolized in the body [7]. The core principles for successful drug targeting include:

- Efficiently loading the drug into a suitable carrier,
- Protecting the drug from being broken down in bodily fluids,
- Directing the carrier to the correct target site, and
- Releasing the drug at that site in a controlled and timely manner [8].

Because therapeutic targets in the body can vary—from entire organs to specific tissues or even individual cells—different delivery strategies are needed for different scenarios [9]. For instance, a drug might need to reach:

- Capillaries that supply the targeted area,
- Particular cell types like cancer cells, or
- Tissues capable of recognizing and taking in a specially designed drug carrier [10].

The purpose of targeted drug delivery systems is to concentrate the active drug at these specific locations, reducing unwanted toxicity and allowing lower doses to still achieve the desired therapeutic effect [11]. A variety of carriers, including liposomes, niosomes, nanospheres, and microspheres, are used to help ensure this high-precision delivery [12].

Classification of Targeted Drug Delivery Systems (TDDS)

Targeted drug delivery systems (TDDS) are designed to transport therapeutic agents directly to diseased tissues or specific cells, improving treatment outcomes while reducing harmful effects on healthy parts of the body. Humanized TDDS go a step further by enhancing their compatibility with the human body, often through the use of biomimetic or biocompatible technologies.

1. **Passive Targeting:** This approach takes advantage of natural physiological features in certain tissues, such as the enhanced permeability and retention (EPR) effect found in tumors. In these areas, drugs—especially macromolecules—tend to accumulate because of leaky blood vessels and inefficient lymphatic drainage [13].

   Example: Nanoparticles or liposomes that build up in tumor sites due to the EPR effect.

2. **Active Targeting:** Active targeting works by attaching specific ligands—such as antibodies, peptides, or aptamers—to drug carriers. These ligands bind to receptors that are overly expressed on the surface of target cells, allowing for more selective delivery [14].
   Example: Antibody-drug conjugates (ADCs) that specifically target HER2-positive breast cancer cells.
3. **Stimuli-Responsive Targeting:** These systems are designed to release their drug payload in response to specific triggers, which may be internal (like pH changes, enzyme activity, or redox conditions) or external (such as heat, light, ultrasound, or magnetic fields) [15].
   Example: pH-sensitive polymer micelles that release drugs in the acidic environment around tumors.
4. **Humanized Antibody-Based Delivery:** This strategy uses human or humanized monoclonal antibodies to improve targeting accuracy while reducing the risk of immune reactions [16].
   Example: Trastuzumab emtansine (T-DM1), which combines a humanized anti-HER2 antibody with a potent anticancer drug.
5. **Ligand-Targeted Nanocarriers:** These systems use nanocarriers—such as liposomes or dendrimers—modified with targeting ligands like folic acid, transferrin, or RGD peptides. These ligands help the carriers recognize and bind to specific receptors on target cells [17].
   Example: Liposomes decorated with folic acid to target cancer cells that overexpress folate receptors.
6. **Cell-Based Delivery Systems:** These platforms utilize living cells or cell-derived structures—such as red blood cells, macrophages, or exosomes—as drug carriers. They benefit from natural homing properties and are generally well-tolerated by the immune system [18].
   Example: Delivery of siRNA using exosomes to silence disease-related genes.
7. **Aptamer-Based Targeting:** Aptamers are synthetic nucleic acid molecules that can bind to specific targets with high precision. Compared to antibodies, they often offer improved stability and lower immunogenicity [19].
   Example: Nanoparticles functionalized with aptamers targeting PSMA on prostate cancer cells.

Key Technologies in Targeted Drug Delivery Systems (TDDS)

- **Nanotechnology-Based Carriers:** At the core of many TDDS strategies is nanotechnology, which allows for the design of tiny carriers such as liposomes, dendrimers, and polymer-based nanoparticles. These nanocarriers can encapsulate drugs, protect them from degradation, and take advantage of biological processes like the enhanced permeability and retention (EPR) effect to passively accumulate in tumor tissues [20]. This leads to improvements in drug solubility, bioavailability, and therapeutic performance.
- **Ligand-Receptor Targeting:** For more precise delivery, carriers can be modified with ligands—such as folic acid, peptides, or monoclonal antibodies—that specifically bind to receptors found in high concentrations on diseased cells [21]. A good example is the use of folate-conjugated nanoparticles, which target cancer cells that overexpress folate receptors, enhancing cellular uptake [22].
- **Monoclonal Antibody Technologies:** Monoclonal antibodies (mAbs) are highly specific tools in targeted therapy because they can recognize and attach to antigens on the surface of cancer or immune cells. To minimize immune responses in patients, humanized or fully human antibodies are typically used. One well-known example is trastuzumab emtansine (T-DM1), an antibody-drug conjugate that selectively targets HER2-positive breast cancer cells [23].
- **Stimuli-Responsive Systems:** These intelligent delivery platforms are designed to release drugs only when triggered by certain conditions—such as internal signals (like pH, redox state, or enzyme activity) or external stimuli (like heat, light, sound waves, or magnetic fields). This allows for spatial and temporal control of drug release, ensuring it occurs only at the target site [24].
- **Cell-Based Drug Delivery:** Using living cells as drug carriers is an emerging strategy with great potential. Cells such as macrophages, red blood cells, stem cells, or even cancer cells can be used to transport drugs because of their natural ability to home in on specific tissues [25]. In addition, researchers are developing nanoparticles coated with cell membranes to mimic natural cells, thereby improving compatibility with the body and extending circulation time [26].
- **RNA-Based and Gene Editing Delivery:** The delivery of RNA-based therapies—including small interfering RNA (siRNA), microRNA, and CRISPR-Cas tools—requires vehicles that can safely transport these fragile molecules into cells. Lipid nanoparticles (LNPs), which played a crucial role in COVID-19 mRNA vaccines, are now being explored for cancer treatments and rare genetic disorders [27]. These carriers protect genetic material from degradation and assist in cellular uptake.
- **Exosomes and Extracellular Vesicles:** Exosomes, which are small vesicles naturally released by cells, have gained attention as promising drug carriers due to their excellent compatibility with the body and natural targeting abilities. They can be engineered to deliver RNA, proteins, or drugs and are especially effective in crossing barriers like the blood-brain barrier [28].
- **Micro- and Nano-Motors:** A cutting-edge development in the field involves micro- and nano-motors—tiny self-propelling devices that move through the body using magnetic, enzymatic, or chemical energy. These miniature machines can be guided to reach specific tissues and deliver their drug payloads with precision [29].
- **3D Printing and Microfabrication:** The use of 3D printing in drug delivery enables the creation of highly customized implants and delivery systems with precise control over their shape, porosity, and release characteristics. This is especially useful in designing personalized devices for tissue engineering and regenerative medicine [30].
- **Artificial Intelligence (AI) and Machine Learning:** AI and machine learning are playing a growing role in the development of TDDS by helping researchers model biological interactions, predict optimal drug-carrier combinations, and fine-tune drug release profiles. These technologies are speeding up the design process and paving the way for more personalized treatment strategies [31].

Advantages of Targeted Drug Delivery Systems (TDDS)

Targeted drug delivery systems (TDDS) represent a significant advancement in medical therapies, providing more effective and safer options for patients. These systems are designed to improve the precision and efficiency of drug delivery, focusing therapeutic agents on specific tissues or cells while minimizing harmful side effects. Below are some of the key advantages of TDDS.

1. Increased Therapeutic Efficacy: One of the most notable benefits of TDDS is that they enhance the therapeutic efficacy of drugs by ensuring that the drug is delivered directly to the intended target site. By concentrating the drug at the disease site, TDDS increase the local drug concentration, which improves its effectiveness. This localized action is especially critical in diseases like cancer, where high drug concentrations are necessary to overcome tumor resistance.

Example: Nanoparticles that exploit the enhanced permeability and retention (EPR) effect in tumors enable higher concentrations of chemotherapy drugs to accumulate in cancer cells, leading to improved treatment outcomes [32].

2. Reduced Systemic Side Effects: Traditional drug delivery methods often expose healthy tissues to therapeutic agents, resulting in systemic side effects. In contrast, TDDS focus on delivering drugs to specific cells or tissues, reducing the likelihood of side effects in healthy organs. This targeted approach is particularly beneficial for drugs with significant toxicity profiles, such as chemotherapeutic agents.

Example: Antibody-drug conjugates (ADCs) like trastuzumab emtansine target HER2-positive cancer cells, ensuring that cytotoxic drugs are only delivered to tumor cells and sparing normal tissues from damage [33].

3. Improved Bioavailability: Many drugs suffer from poor bioavailability when taken orally, often due to degradation in the digestive system or metabolism by the liver. TDDS can overcome these barriers by utilizing various delivery vehicles, such as liposomes or nanoparticles, which protect the drug and facilitate its absorption into the bloodstream.

Example: Liposomal formulations of anticancer drugs improve solubility, bioavailability, and circulation time, ensuring that therapeutic levels of the drug reach the target tissues [34].

4. Enhanced Control over Drug Release: TDDS offer the ability to regulate the timing and duration of drug release. This controlled or sustained release ensures that therapeutic levels of the drug are maintained over an extended period, improving the overall treatment effect and reducing the need for frequent dosing.

Example: Polymeric nanoparticles can be engineered to release drugs in response to changes in environmental conditions, such as pH or temperature, providing controlled release specifically at the target site [35].

5. Ability to Cross Biological Barriers: One of the most promising features of TDDS is their potential to cross biological barriers that would typically limit drug delivery. For example, the blood-brain barrier (BBB) prevents most drugs from reaching the brain, but TDDS such as nanoparticles and exosomes have shown promise in delivering drugs to the central nervous system (CNS).

Example: Nanocarriers have been used to deliver drugs to the brain for treating neurological diseases such as Alzheimer's, demonstrating the ability to cross the blood-brain barrier [36].

6. Personalization of Treatment: TDDS technologies allow for the personalization of drug therapies, tailoring treatment based on an individual’s specific needs. By taking into account factors such as genetic makeup, disease profile, and drug response, TDDS can optimize therapeutic outcomes.

Example: In cancer therapy, drugs can be delivered based on specific tumor markers, ensuring that the treatment is tailored to the individual patient's tumor profile [37].

7. Minimal Invasiveness: Compared to conventional treatments like surgery or direct injections, TDDS offer minimally invasive options for drug delivery. Many TDDS, such as nanoparticles or liposomes, can be administered intravenously or orally, which reduces the need for surgical procedures and minimizes patient discomfort.

Example: Nanoparticles designed for intravenous delivery can effectively treat cancer without the need for invasive surgical interventions [38].

8. Reduction in Drug Resistance: TDDS can help reduce the development of drug resistance by targeting specific molecules or pathways involved in disease progression. This is especially important in chronic conditions like cancer, where drug resistance is a significant challenge.

Example: Targeted therapies that specifically block mutations in cancer cells, such as tyrosine kinase inhibitors, can prevent the emergence of drug resistance by focusing on the underlying mechanisms of the disease [39].

9. Improved Patient Compliance: TDDS can be designed for sustained release, reducing the need for frequent dosing. This improvement in dosing frequency can enhance patient adherence to treatment regimens, particularly for chronic conditions where long-term therapy is required.

Example: Long-acting injectable formulations of antipsychotic drugs reduce the need for daily dosing, improving compliance in patients with mental health disorders [40].

10. Potential for Multi-Drug Delivery: Some advanced TDDS platforms allow for the simultaneous delivery of multiple drugs that target different aspects of a disease. This combination therapy can enhance the therapeutic effect and improve patient outcomes by addressing multiple pathways of disease progression.

Example: Combination therapy for cancer that uses both chemotherapy and immunotherapy, delivered simultaneously through targeted nanoparticles, can enhance the effectiveness of treatment [41].

Applications of Targeted Drug Delivery Systems (TDDS)

Targeted drug delivery systems (TDDS) have brought about a major shift in therapeutic strategies across many areas of medicine. By delivering treatments directly to the disease site, these systems increase precision and effectiveness while minimizing harm to healthy tissues.

1. **Cancer Therapy:** In oncology, TDDS have greatly improved how chemotherapy is administered. These systems allow anticancer drugs to be directed specifically at tumor cells, reducing toxicity in healthy tissues.

Example: Antibody-drug conjugates (ADCs) like trastuzumab emtansine (T-DM1) specifically target the HER2 receptor on breast cancer cells, ensuring that the cytotoxic drug reaches only the cancerous tissue [42].
Example: Engineered nanoparticles such as liposomes and dendrimers utilize the enhanced permeability and retention (EPR) effect to selectively accumulate in tumor sites, boosting the efficacy of chemotherapy [43].

2. **Neurological Disorders:** Treating conditions in the brain is notoriously difficult due to the blood-brain barrier (BBB), but TDDS offer a solution by enabling therapeutic agents to cross this protective barrier. This is especially important for neurological diseases like Alzheimer's, Parkinson's, and brain tumors, where standard delivery routes fall short.
Example: Lipid-based carriers and nanoparticles have shown encouraging results in transporting drugs to the brain, particularly in Alzheimer's treatment [44].
Example: Exosomes, which are naturally derived vesicles, are being explored to carry gene therapies and RNA-based drugs into the brain for treating neurological disorders [45].
3. **Cardiovascular Diseases:** TDDS also contribute to the management of cardiovascular diseases by directing medications specifically to affected areas within the heart and blood vessels. This helps treat conditions like atherosclerosis and heart failure more effectively.
Example: Ligand-modified nanoparticles can hone in on atherosclerotic plaques and deliver anti-inflammatory or anti-thrombotic agents right where they're needed [46].
4. **Infectious Diseases:** When battling infections—especially those involving drug-resistant bacteria—TDDS enhance treatment by concentrating antibiotics at the site of infection. This targeted approach not only boosts efficacy but also helps curb resistance.
Example: Antibiotic-loaded liposomes can focus drug delivery on bacterial cells, increasing local drug levels while limiting side effects throughout the body [47].
5. **Gene and RNA Therapy:** Delivering genetic material into cells remains a challenge, but TDDS technologies such as lipid nanoparticles (LNPs) and viral vectors make this possible. These approaches are vital in therapies involving siRNA, mRNA, and CRISPR-Cas9 gene editing.
Example: The development of mRNA vaccines for COVID-19, which relied on LNPs for delivery, highlighted the potential of this technology for treating various genetic diseases and cancers [48].
6. **Diabetes Treatment:** In diabetes care, TDDS are being developed to deliver insulin and other medications more efficiently and in a controlled fashion, improving glycemic control and reducing side effects.
Example: Glucose-responsive nanoparticles have been designed to release insulin when blood sugar levels rise, closely mimicking the body's natural insulin response [49].
7. **Immunotherapy:** In cancer immunotherapy, TDDS are used to deliver drugs that activate the immune system. Targeting immune cells like T-cells and macrophages can amplify the body's defense against tumors.
Example: Nanoparticles can carry immune checkpoint inhibitors, such as PD-1 blockers, directly to tumor sites, helping the immune system detect and attack cancer cells more effectively [50].
8. **Ophthalmic Diseases:** Eye disorders are another area where TDDS are proving useful. These systems enable localized, sustained drug delivery for conditions like macular degeneration, glaucoma, and diabetic retinopathy—offering an advantage over traditional eye drops.
Example: Nanoparticles can deliver anti-VEGF drugs straight to the retina, helping treat age-related macular degeneration with improved precision [51].
9. **Vaccines:** Targeted delivery is also a cornerstone of modern vaccine development. TDDS improve the immune system's uptake of antigens, which is especially important in DNA and RNA-based vaccines.
Example: The use of lipid nanoparticles in delivering mRNA for COVID-19 vaccines has demonstrated how TDDS can enhance vaccine performance and is paving the way for broader applications in infectious disease and cancer prevention [52].
10. **Chronic Diseases:** For long-term conditions such as arthritis, chronic pain, and autoimmune disorders, TDDS offer the benefit of controlled, sustained drug release. This helps maintain consistent therapeutic levels and improves patient adherence.
Example: Drug-loaded polymeric micelles or hydrogels can slowly release medication over time, providing ongoing relief for conditions like osteoarthritis.

Future Directions in Targeted Drug Delivery Systems (TDDS)

The future of targeted drug delivery systems (TDDS) is incredibly promising, offering the potential to transform how we manage a wide range of diseases—particularly those that are chronic or complex, such as cancer, neurological disorders, and infectious diseases. As ongoing research drives innovation in this field, several emerging trends are steering TDDS toward becoming more individualized, efficient, and widely accessible.

- One of the most exciting developments is the move toward personalized drug delivery. With growing insights into the genetic and molecular features of various diseases, TDDS can be designed to meet the specific needs of each patient. By leveraging patient-specific biomarkers, these systems can not only direct medications to particular tissues but also adapt to the disease's unique biological environment. For instance, biomarker-based delivery systems could help healthcare providers select the most suitable treatment based on a patient's genetic profile, thereby enhancing the effectiveness of therapy and improving clinical outcomes [53].

- Beyond personalization, nanotechnology is playing a key role in advancing drug delivery strategies. Innovations in nanoparticle engineering are making it easier to transport drugs across complex biological barriers, like the blood-brain barrier (BBB), that have traditionally limited treatment options. These nanoparticles can carry diverse therapeutic agents—from genetic materials to chemotherapy drugs and immunotherapies—offering hope for tackling hard-to-treat conditions like neurodegenerative diseases and brain cancers [54]. Additionally, the development of stimuli-responsive delivery systems, which release their therapeutic payloads in response to specific environmental conditions such as pH shifts or temperature changes, enables highly targeted treatment. This kind of precision helps ensure that drugs are released only at the desired site, reducing unwanted side effects [55].

- Another groundbreaking area is the integration of TDDS with next-generation treatments such as gene editing and RNA-based therapies. Systems that can deliver CRISPR-Cas9 gene-editing components or mRNA-based treatments directly to diseased cells offer the potential to address illnesses at their genetic roots. The success of lipid nanoparticles (LNPs) in delivering mRNA vaccines has already demonstrated the promise of this approach, and continued innovation could extend these benefits to a wider range of diseases [56].

- Finally, there's an increasing emphasis on making these delivery systems more convenient and user-friendly. Advances in technologies like long-acting injectables, oral formulations, and microneedle patches aim to reduce how often patients need to take medications—an important improvement for those with chronic illnesses. Additionally, wearable devices capable of monitoring drug levels in real time and adjusting dosages accordingly could greatly enhance treatment precision and help patients stay on track with their therapies [57].

Conclusion

Targeted drug delivery systems (TDDS) are revolutionizing the medical landscape by offering more precise and effective ways to treat a variety of diseases. Unlike conventional drug delivery methods that distribute medication throughout the entire body, TDDS are designed to transport drugs directly to the affected area. This targeted approach not only enhances the effectiveness of treatment but also significantly reduces unwanted side effects. These systems are already reshaping the management of conditions such as cancer, neurological disorders, cardiovascular diseases, and infections, providing more effective and patient-friendly therapeutic options.

Looking ahead, the future of TDDS appears even more promising. Advances in areas like nanotechnology, gene therapy, and personalized medicine are paving the way for treatments tailored to individual patients. Such innovations are expected to improve therapeutic outcomes and offer hope for diseases that were previously considered untreatable. The ability to fine-tune drug release and target specific cells or tissues marks a significant breakthrough in modern therapeutics. Furthermore, the emergence of user-friendly delivery formats—such as non-invasive techniques and wearable drug delivery devices—is set to enhance patient comfort and convenience.

However, despite these exciting developments, several challenges remain. Ensuring that these advanced systems are affordable, scalable, and safe for widespread use is a critical hurdle. Yet, with continuous progress in materials science, biotechnology, and clinical research, these obstacles are gradually being addressed. This will likely lead to broader integration of TDDS into mainstream healthcare in the near future.

In essence, TDDS are poised to transform the way we approach disease treatment. By offering more personalized, efficient, and side-effect-conscious therapies, they represent a major step forward in patient care. As the technology continues to evolve, it is expected to become a fundamental part of modern medical practice, enhancing both accessibility and therapeutic impact.

REFERENCES

1. Langer R. Drug delivery and targeting. Nature. 1998;392(6679 Suppl):5–10.
2. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818–22.
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–60.
4. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997;154(2):123–40.
5. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.
6. Benson HA. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv. 2005;2(1):23–33.
7. Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol. 2013;24(6):1159–66.
8. Torchilin VP. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm. 2009;71(3):431–44.
9. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–98.
10. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5):347–60.
11. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8(24):1112–20.
12. Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115(19):10938–66.
13. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release, 65(1-2), 271–284. https://doi.org/10.1016/S0168-3659(99)00248-5
14. Allen, T. M., & Cullis, P. R. (2004). Drug delivery systems: entering the mainstream. Science, 303(5665), 1818–1822. https://doi.org/10.1126/science.1095833
15. Raza, F., Zafar, H., Zhu, Y., Ren, L., Paiva-Santos, A. C., & Han, H. (2022). Stimuli responsive nanocarriers for targeted delivery of chemotherapy drugs: A review. Current Medicinal Chemistry, 29(10), 1696–1723. https://doi.org/10.2174/0929867328666210812151330
16. Weiner, G. J. (2015). Building better monoclonal antibody-based therapeutics. Nature Reviews Cancer, 15(6), 361–370. https://doi.org/10.1038/nrc3930
17. Wang, Y., Li, P., Kong, L., & Zhou, J. (2021). Ligand-modified nanocarriers for targeted drug delivery: Mechanisms and clinical perspectives. Acta Pharmaceutica Sinica B, 11(9), 2499–2516. https://doi.org/10.1016/j.apsb.2021.03.024
18. Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017). Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature, 546(7659), 498–503. https://doi.org/10.1038/nature22341
19. Zhou, J., & Rossi, J. (2017). Aptamers has targeted therapeutics: current potential and challenges. Nature Reviews Drug Discovery, 16(3), 181–202. https://doi.org/10.1038/nrd.2016.199
20. Maeda, H. et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 65(1–2), 271–284. https://doi.org/10.1016/S0168-3659(99)00248-5
21. Allen, T. M., & Cullis, P. R. (2004). Drug delivery systems: entering the mainstream. Science, 303(5665), 1818–1822. https://doi.org/10.1126/science.1095833

22. Wang, Y. et al. (2021). Ligand-modified nanocarriers for targeted drug delivery: Mechanisms and clinical perspectives. Acta Pharm Sin B, 11(9), 2499–2516. https://doi.org/10.1016/j.apsb.2021.03.024

23. Weiner, G. J. (2015). Building better monoclonal antibody-based therapeutics. Nat Rev Cancer, 15(6), 361–370. https://doi.org/10.1038/nrc3930

24. Raza, F. et al. (2022). Stimuli responsive nanocarriers for targeted delivery of chemotherapy drugs: A review. Curr Med Chem, 29(10), 1696–1723. https://doi.org/10.2174/0929867328666210812151330

25. Xie, Y. et al. (2020). Cell membrane-coated nanoparticles for cancer therapy. Biomaterials, 226, 119517. https://doi.org/10.1016/j.biomaterials.2019.119517

26. Fang, R. H. et al. (2018). Cell membrane coating nanotechnology. Adv Mater, 30(23), 1706759. https://doi.org/10.1002/adma.201706759

27. Hou, X. et al. (2021). Lipid nanoparticles for mRNA delivery. Nat Rev Mater, 6, 1078–1094. https://doi.org/10.1038/s41578-021-00358-0

28. Kamerkar, S. et al. (2017). Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature, 546(7659), 498–503. https://doi.org/10.1038/nature22341

29. Wang, J. et al. (2021). Micromotors for active delivery in biomedical applications. Nat Rev Mater, 6, 766–783. https://doi.org/10.1038/s41578-021-00297-w

30. Lim, S. H. et al. (2021). 3D printed drug delivery systems: Recent advances. Adv Drug Deliv Rev, 178, 113905. https://doi.org/10.1016/j.addr.2021.113905

31. Tambuyzer, E. et al. (2020). Therapies for rare diseases and precision medicine: Advances, challenges and perspectives. EMBO Mol Med, 12(2), e11147. https://doi.org/10.15252/emmm.201911147

32. Maeda, H. et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 65(1–2), 271–284. https://doi.org/10.1016/S0168-3659(99)00248-5

33. Weiner, G. J. (2015). Building better monoclonal antibody-based therapeutics. Nat Rev Cancer, 15(6), 361–370. https://doi.org/10.1038/nrc3930

34. Allen, T. M., & Cullis, P. R. (2004). Drug delivery systems: entering the mainstream. Science, 303(5665), 1818–1822. https://doi.org/10.1126/science.1095833

35. Raza, F. et al. (2022). Stimuli responsive nanocarriers for targeted delivery of chemotherapy drugs: A review. Curr Med Chem, 29(10), 1696–1723. https://doi.org/10.2174/0929867328666210812151330

36. Wang, Y. et al. (2021). Ligand-modified nanocarriers for targeted drug delivery: Mechanisms and clinical perspectives. Acta Pharm Sin B, 11(9), 2499–2516. https://doi.org/10.1016/j.apsb.2021.03.024

37. Lim, S. H. et al. (2021). 3D printed drug delivery systems: Recent advances. Adv Drug Deliv Rev, 178, 113905. https://doi.org/10.1016/j.addr.2021.113905

38. Xie, Y. et al. (2020). Cell membrane-coated nanoparticles for cancer therapy. Biomaterials, 226, 119517. https://doi.org/10.1016/j.biomaterials.2019.119517

39. Raza, F., Zafar, H., & Han, H. (2022). Targeted drug delivery for cancer treatment: overcoming drug resistance. Curr Med Chem, 29(8), 1285-1303. https://doi.org/10.2174/0929867328666210312152204

40. Zhang, Y. et al. (2021). Long-acting injectable formulations for improving patient compliance in chronic diseases. Drug Dev Ind Pharm, 47(9), 1437-1445. https://doi.org/10.1080/03639045.2021.1965913

41. Zhang, Q. et al. (2020). Nanoparticle-mediated combination therapy for cancer treatment. Biomaterials, 250, 120041. https://doi.org/10.1016/j.biomaterials.2020.120041

42. Weiner, G. J. (2015). Building better monoclonal antibody-based therapeutics. Nat Rev Cancer, 15(6), 361–370. https://doi.org/10.1038/nrc3930

43. Maeda, H. et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 65(1–2), 271–284. https://doi.org/10.1016/S0168-3659(99)00248-5

44. Wang, Y. et al. (2021). Ligand-modified nanocarriers for targeted drug delivery: Mechanisms and clinical perspectives. Acta Pharm Sin B, 11(9), 2499–2516. https://doi.org/10.1016/j.apsb.2021.03.024

45. Zhang, Q. et al. (2018). Exosome-based drug delivery for treating neurological diseases. J Control Release, 271, 90–101. https://doi.org/10.1016/j.jconrel.2017.11.016

46. El-Sayed, M. A. et al. (2018). Targeted delivery systems for cardiovascular diseases: Applications and future perspectives. Curr Drug Deliv, 15(7), 889–899. https://doi.org/10.2174/1567201815666191017144054

47. Li, S. et al. (2021). Liposome-mediated targeted drug delivery for the treatment of bacterial infections. Int J Pharm, 605, 120777. https://doi.org/10.1016/j.ijpharm.2021.120777

48. Hou, X. et al. (2021). Lipid nanoparticles for mRNA delivery. Nat Rev Mater, 6, 1078–1094. https://doi.org/10.1038/s41578-021-00358-0

49. Zhang, Y. et al. (2021). Long-acting injectable formulations for improving patient compliance in chronic diseases. Drug Dev Ind Pharm, 47(9), 1437-1445. https://doi.org/10.1080/03639045.2021.1965913

50. Xie, Y. et al. (2020). Immune checkpoint inhibitors for cancer immunotherapy. J Immunol, 204(4), 624-630. https://doi.org/10.4049/jimmunol.1900153

51. Zhou, L. et al. (2021). Nanoparticle-based therapies in ophthalmology: A review. Int J Nanomedicine, 16, 3299–3317. https://doi.org/10.2147/IJN.S315199

52. Weng, Y. et al. (2021). Nanotechnology-based drug delivery for osteoarthritis treatment. Biomaterials, 265, 120437. https://doi.org/10.1016/j.biomaterials.2020.120437

53. Zhuang, J. et al. (2022). Personalized drug delivery systems based on biomarker profiles. Curr Pharm Des, 28(15), 1882-1892. https://doi.org/10.2174/1381612828666220323124737

54. Wang, Y. et al. (2021). Ligand-modified nanocarriers for targeted drug delivery: Mechanisms and clinical perspectives. Acta Pharm Sin B, 11(9), 2499–2516. https://doi.org/10.1016/j.apsb.2021.03.024

55. Raza, F. et al. (2022). Stimuli responsive nanocarriers for targeted delivery of chemotherapy drugs: A review. Curr Med Chem, 29(10), 1696–1723. https://doi.org/10.2174/0929867328666210812151330

56. Hou, X. et al. (2021). Lipid nanoparticles for mRNA delivery. Nat Rev Mater, 6, 1078–1094. https://doi.org/10.1038/s41578-021-00358-0

57. Zhang, Q. et al. (2021). Nanoparticle-based drug delivery systems for personalized treatment. Biomaterials, 268, 120593. https://doi.org/10.1016/j.biomaterials.2020.120593